GU Cancer
Breast Cancer
Lung Cancer
GI Cancer
Logo
Conference Coverage
Podcasts
Video
Other Cancers
Logo
Differentiated Thyroid CancerPancreatic CancerColorectal CancerBreast Cancer - RoundtableMIBC - RoundtableRCC - RoundtableNSCLCESMO 2026 NSCLC RoundtablenccRCC

Latest Videos

Overcoming Resistance in HER2-Mutant NSCLC

Overcoming Resistance in HER2-Mutant NSCLC

Sequencing HER2-Directed Therapies in NSCLC

Sequencing HER2-Directed Therapies in NSCLC

DESTINY-Lung04: Frontline T-DXd Efficacy and ILD Management in HER2-Mutant NSCLC

DESTINY-Lung04: Frontline T-DXd Efficacy and ILD Management in HER2-Mutant NSCLC

Differentiated Thyroid Cancer

View All
Neoadjuvant Therapy in Advanced Thyroid Cancer: Surgical Impact & Evolving Challenges

Neoadjuvant Therapy in Advanced Thyroid Cancer: Surgical Impact & Evolving Challenges

Real-World Risks & Future Tech in Thyroid Cancer Surgery with Dr. Greg Randolph

Real-World Risks & Future Tech in Thyroid Cancer Surgery with Dr. Greg Randolph

Q&A with Dr. Greg Randolph: How Neural Monitoring Is Changing Thyroid Cancer Surgery

Q&A with Dr. Greg Randolph: How Neural Monitoring Is Changing Thyroid Cancer Surgery

Pancreatic Cancer

View All
Targeting KRAS in Pancreatic Cancer

Targeting KRAS in Pancreatic Cancer

Colorectal Cancer

View All
Dr. Nicholas Hornstein: A Turning Point in Colorectal Cancer Treatment

Dr. Nicholas Hornstein: A Turning Point in Colorectal Cancer Treatment

Breast Cancer - Roundtable

View All
Drs. Mahtani, McArthur, & O’Dea Break Down DESTINY-Breast09, PATINA, & HER2CLIMB-05

Drs. Mahtani, McArthur, & O’Dea Break Down DESTINY-Breast09, PATINA, & HER2CLIMB-05

T-DXd Moves Earlier in HER2+ Breast Cancer: DESTINY-Breast05 & DB-11

T-DXd Moves Earlier in HER2+ Breast Cancer: DESTINY-Breast05 & DB-11

SABCS 2025: Platinum and Neoadjuvant Strategies in Early TNBC

SABCS 2025: Platinum and Neoadjuvant Strategies in Early TNBC

MIBC - Roundtable

View All
What’s Next in Bladder Cancer Treatment?

What’s Next in Bladder Cancer Treatment?

Biomarkers, Frailty, and Implementing EV-Pembro in Bladder Cancer Care

Biomarkers, Frailty, and Implementing EV-Pembro in Bladder Cancer Care

Implementing KEYNOTE-905 & KEYNOTE-B15 in Community Practice

Implementing KEYNOTE-905 & KEYNOTE-B15 in Community Practice

RCC - Roundtable

View All
Future Directions in RCC: Triplets, Biomarkers, and Neoadjuvant Strategies

Future Directions in RCC: Triplets, Biomarkers, and Neoadjuvant Strategies

Expanding Adjuvant Therapy in RCC

Expanding Adjuvant Therapy in RCC

Sequencing Lenvatinib-Based Therapy in Refractory RCC

Sequencing Lenvatinib-Based Therapy in Refractory RCC

NSCLC

View All
Sequencing Therapy in EGFR-Mutant NSCLC

Sequencing Therapy in EGFR-Mutant NSCLC

ESMO 2026 NSCLC Roundtable

View All
Overcoming Resistance in HER2-Mutant NSCLC

Overcoming Resistance in HER2-Mutant NSCLC

Sequencing HER2-Directed Therapies in NSCLC

Sequencing HER2-Directed Therapies in NSCLC

DESTINY-Lung04: Frontline T-DXd Efficacy and ILD Management in HER2-Mutant NSCLC

DESTINY-Lung04: Frontline T-DXd Efficacy and ILD Management in HER2-Mutant NSCLC

nccRCC

View All
NCCN Guidelines and Treatment Selection in Non–Clear Cell RCC

NCCN Guidelines and Treatment Selection in Non–Clear Cell RCC

Logo
AboutContactPrivacy PolicyTerms of Use

© 2026 OncologyNexus. All rights reserved.